Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder

被引:10
作者
Zeifman, Richard J. [1 ,5 ]
Kettner, Hannes [2 ]
Ross, Stephen [1 ]
Weiss, Brandon [2 ]
Mithoefer, Michael C. [3 ]
Mithoefer, Ann T. [3 ]
Wagner, Anne C. [4 ]
机构
[1] NYU Langone Ctr Psychedel Med, NYU Grossman Sch Med, Dept Psychiat, New York, NY USA
[2] Imperial Coll London, Fac Med, Ctr Psychedel Res, Dept Brain Sci, London, England
[3] MAPS Publ Benefit Corp MPBC, San Jose, CA USA
[4] Toronto Metropolitan Univ, Dept Psychol, Toronto, ON, Canada
[5] NYU Langone Ctr Psychedel Med, NYU Grossman Sch Med, Dept Psychiat, 1 Pk Ave, New York, NY 10016 USA
基金
加拿大健康研究院;
关键词
Posttraumatic stress disorder; MDMA; MDMA-assisted psychotherapy; therapeutic alliance; mechanism of change; Trastorno de estres postraumatico; Psicoterapia asistida por MDMA; alianza terapeutica; mecanismos de cambio; 3,4-METHYLENEDIOXYMETHAMPHETAMINE-ASSISTED PSYCHOTHERAPY; COMMON FACTORS; GROUP COHESION; EXPERIENCES; PSILOCYBIN; RESISTANT; ADDRESS; SAFETY; TIME; 1ST;
D O I
10.1080/20008066.2023.2297536
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: MDMA-assisted psychotherapy (MDMA-AP) is a combined psychotherapeutic and pharmacologic intervention that shows promise in the treatment of posttraumatic stress disorder (PTSD). Although therapeutic alliance has been established as a key predictor across psychotherapies and is emphasised within MDMA-AP treatment manuals, research has not yet examined the relationship between therapeutic alliance and MDMA-AP treatment outcomes.Objective: Examine whether therapeutic alliance predicts changes in PTSD symptoms following MDMA-AP.Method: Twenty-three individuals with chronic PTSD participated in a MDMA-AP clinical trial that included a randomised (MDMA vs. placebo) and open-label phase. The present analyses focused on participants who were administered MDMA over the course of the randomised and open-label phases (n = 22). Therapeutic alliance was assessed using the Working Alliance Inventory at sessions baseline (pre-session 3) and sessions 4 and 9. PTSD symptoms were assessed using the Clinician Administered PTSD Scale and the Impact of Events Scale-Revised.Results: Controlling for baseline clinician-assessed PTSD severity, therapeutic alliance at sessions 4 and 9 (but not baseline) significantly predicted post-MDMA-AP clinician-assessed PTSD severity. Controlling for baseline self-reported PTSD severity, therapeutic alliance at baseline (although this did not survive correction for multiple comparisons) and sessions 4 and 9 predicted post-MDMA-AP self-reported PTSD severity.Conclusions: The present results provide the first preliminary evidence for the relationship between the therapeutic alliance and treatment outcomes within MDMA-AP for PTSD. These findings highlight the important role of psychotherapy, and common psychotherapeutic factors, within MDMA-AP. Replication in studies with larger and more diverse clinical samples remain necessary.Trial registration: ClinicalTrials.gov identifier: NCT00090064. Among individuals with chronic posttraumatic stress disorder, therapeutic alliance predicted changes in posttraumatic stress disorder severity following MDMA-assisted psychotherapy.Therapeutic alliance may play a key role in facilitating therapeutic improvement within MDMA-assisted psychotherapy.Further research remains necessary to confirm these preliminary findings and the role of therapeutic alliance in MDMA-assisted psychotherapy. Antecedentes: La psicoterapia asistida por MDMA (MDMA-AP por sus siglas en ingles) es una combinacion de intervencion psicoterapeutica y farmacologica que muestra ser prometedora en el tratamiento del trastorno de estres postraumatico (TEPT). Aunque la alianza terapeutica ha sido bien establecida como un predictor clave a traves de las psicoterapias y se enfatiza en los manuales de tratamiento MDMA-AP, la investigacion aun no ha examinado la relacion entre la alianza terapeutica y los resultados del tratamiento MDMA-AP.Objetivo: Examinar si la alianza terapeutica predice cambios en los sintomas de TEPT despues de MDMA-AP.Metodo: Veintitres individuos con TEPT cronico participaron en un ensayo clinico de MDMA-AP que incluyo una fase aleatorizada (MDMA vs placebo) y abierta. El presente analisis se centra en los participantes a los que se les administro MDMA en el curso de las fases aleatorias y abiertas (n = 22). La alianza terapeutica se evaluo utilizando el Inventario de Alianza de Trabajo en las sesiones iniciales (antes de la sesion 3) y en las sesiones 4 y 9. Los sintomas de TEPT se evaluaron utilizando la Escala de TEPT administrada por el Clinico y la Escala Revisada del Impacto de los Eventos.Resultados: Al controlar segun la severidad del TEPT evaluada por el clinico al inicio, la alianza terapeutica en la sesion 4 y 9 (pero no la inicial) predijo significativamente la severidad del TEPT post tratamiento evaluada por el clinico post MDMA-AP. Al controlar al inicio segun la severidad del TEPT por auto-reporte, la alianza terapeutica al inicio (aunque esto no sobrevivio a la correccion para comparaciones multiples) y en las sesiones 4 y 9 predijeron la severidad del TEPT auto-reportada post-MDMA-AP.Conclusiones: Los resultados actuales proporcionan la primera evidencia preliminar de la relacion entre la alianza terapeutica y los resultados del tratamiento en MDMA-AP para TEPT. Estos hallazgos resaltan el importante papel de la psicoterapia y los factores psicoterapeuticos comunes, dentro de la MDMA-AP. Sigue siendo necesario la replicacion en estudios con muestras clinicas mas grandes y diversas.
引用
收藏
页数:11
相关论文
共 60 条
  • [1] Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca
    Agin-Liebes, Gabrielle
    Zeifman, Richard
    Luoma, Jason B.
    Garland, Eric L.
    Campbell, W. Keith
    Weiss, Brandon
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2022, 36 (03) : 295 - 308
  • [2] American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders, V5th ed., DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]
  • [3] American Psychological Association, 2017, Clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults
  • [4] Effects of MDMA on sociability and neural response to social threat and social reward
    Bedi, Gillinder
    Phan, K. Luan
    Angstadt, Mike
    de Wit, Harriet
    [J]. PSYCHOPHARMACOLOGY, 2009, 207 (01) : 73 - 83
  • [5] Effects of MDMA on attention to positive social cues and pleasantness of affective touch
    Bershad, Anya K.
    Mayo, Leah M.
    Van Hedger, Kathryne
    McGlone, Francis
    Walker, Susannah C.
    de Wit, Harriet
    [J]. NEUROPSYCHOPHARMACOLOGY, 2019, 44 (10) : 1698 - 1705
  • [6] Blake D.D., 1990, The Behavior Therapist, V18, P187
  • [7] Bordin E.S., 1979, Psychotherapy: Theory, Research Practice, V16, P252, DOI [10.1037/h0085885, DOI 10.1037/H0085885]
  • [8] Boritz T. Z., 2018, The Oxford handbook of dialectical behaviour therapy, P515
  • [9] Boyd CE, 2015, AQUACULTURE, RESOURCE USE, AND THE ENVIRONMENT, P1, DOI 10.1002/9781118857915
  • [10] Post-traumatic stress disorder: a state-of-the-art review of evidence and challenges
    Bryant, Richard A.
    [J]. WORLD PSYCHIATRY, 2019, 18 (03) : 259 - 269